Results 211 to 220 of about 119,184 (308)

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B. [PDF]

J Infect Dis
Hume SJ, Visvanathan K, Cheng K, Jackson K, Vogrin S, Hall SAL, Burns GS, Desmond PV, Ratnam D, Levy MT, Sawhney R, Strasser SI, Ngu MC, Sinclair M, Meredith C, Matthews G, Valaydon Z, Wong D, Littlejohn M, Holmes JA, Revill PA, Thompson AJ, Warner N.   +22 more
europepmc   +1 more source

Alpha-interferon induced acute renal allograft rejection [PDF]

, 1995
Holley, JL, Johnson, JP, Jordan, M, Magnone, M, McCauley, J, Scantlebury, V, Shapiro, R, Starzl, T, Vivas, C   +8 more
core  

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China. [PDF]

Ann Med
Peng Y, Liu L, Wu X.
europepmc   +1 more source

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

From Antibiotic Resistance to Bacterial Vaccines: A New Approach to Controlling Resistant Bacterial Infections. [PDF]

Infect Drug Resist
Xiong F, Fang X, Lu Y, Lv W.
europepmc   +1 more source

Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa (EFA) is an ultra–extended half‐life factor VIII (FVIII) developed to address limitations of conventional prophylaxis in haemophilia A. Although the XTEND trials reported low interindividual pharmacokinetic (PK) variability, real‐world data remain important to better characterize PK profiles across patient ...
Laurent Sattler, Agathe Herb, Léa Pierre, Jordan Wimmer, Manon Dolt, Olivier Feugeas, Dominique Desprez   +6 more
wiley   +1 more source

A review of vaccinology and <i>ex vivo</i> antigen-loaded dendritic cells: A different approach to infectious disease vaccines. [PDF]

Hum Vaccin Immunother
Dillman RO, Nistor GI, Keirstead HS.
europepmc   +1 more source

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, EarlyView.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source

MAIT Cells in Liver Disease. [PDF]

Cells
Azad AI, Gutierrez F, Gores GJ.
europepmc   +1 more source